ZRC3308 Monoclonal Antibody Cocktail Shows Protective Efficacy in Syrian Hamsters against SARS-CoV-2 Infection

  • Viruses. 2021 Dec 3;13(12):2424. doi: 10.3390/v13122424.
Pragya D Yadav  1 ,  Sanjeev Kumar Mendiratta  2 ,  Sreelekshmy Mohandas  1 ,  Arun K Singh  2 ,  Priya Abraham  1 ,  Anita Shete  1 ,  Sanjay Bandyopadhyay  2 ,  Sanjay Kumar  3 ,  Aashini Parikh  2 ,  Pankaj Kalita  2 ,  Vibhuti Sharma  2 ,  Hardik Pandya  2 ,  Chirag G Patel  2 ,  Mihir Patel  2 ,  Swagat Soni  2 ,  Suresh Giri  2 ,  Mukul Jain  2
Affiliations
  • 1. Indian Council of Medical Research-National Institute of Virology, Pune 411021, India.
  • 2. Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad 382481, India.
  • 3. Department of Neurosurgery, Command Hospital (Southern Command), Armed Forces Medical College (AFMC), Pune 411040, India.
PMID: 34960695 DOI: 10.3390/v13122424
Abstract

We have developed a monoclonal antibody (mAb) cocktail (ZRC-3308) comprising of ZRC3308-A7 and ZRC3308-B10 in the ratio 1:1 for COVID-19 treatment. The mAbs were designed to have reduced immune effector functions and increased circulation half-life. mAbs showed good binding affinities to non-competing epitopes on RBD of SARS-CoV-2 spike protein and were found neutralizing SARS-CoV-2 variants B.1, B.1.1.7, B.1.351, B.1.617.2, and B.1.617.2 AY.1 in vitro. The mAb cocktail demonstrated effective prophylactic and therapeutic activity against SARS-CoV-2 Infection in Syrian hamsters. The antibody cocktail appears to be a promising candidate for prophylactic use and for therapy in early COVID-19 cases that have not progressed to severe disease.

Keywords
SARS-CoV-2; ZRC3308; hamsters; monoclonal antibody; prophylaxis.
Products